Great coverage of our HU3DINKS project: a collaboration with BIO INX, THT Biomaterials GmbH, UpNano GmbH, MORPHOMED GMBH and Ludwig Boltzmann Institute. This project is an IRASME project funded by VLAIO - Flanders Innovation & Entrepreneurship and FFG Austrian Research Promotion Agency.
Some coverage on the HU3DINKS project. Our CEO Jasper Van Hoorick had the pleasure of being interviewed by Kate Robinson of Technology Networks, about the groundbreaking advancements in 3D bioprinting, the development of Human based #bioinks and the promising future it holds for medicine and research. 🧬 Current Challenges: 3D bioprinting aims to revolutionize fields like regenerative medicine and drug screening. However, there are hurdles to overcome, including regulatory approvals and the need for reliable, high-performing bioinks to keep cells alive during the printing process. 🐾 Shifting from Animal-Based to Human Tissue-Based Bioinks: BIO INX is part of the Human Bioinks for 3D Printing (HU3DINKS) project together with THT Biomaterials GmbH, UpNano GmbH, MORPHOMED GMBH and Ludwig Boltzmann Institute Trauma , focused on developing bioinks from human placenta tissue. This shift from animal-based materials offers several advantages, such as being animal-free, better resembling human ECM, and utilizing a sustainable source. 🚀 The Future of 3D Bioprinting: In the next decade, we might witness the transplantation of 3D-printed tissues using a patient's own cells. Beyond regenerative medicine, 3D bioprinting opens doors for drug screening and cosmetics testing, reducing the need for animal trials and speeding up drug development. 👉 Read the full interview to dive deeper into the world of 3D bioprinting and its game-changing potential: https://lnkd.in/epk6ZdqR #3DBioprinting #RegenerativeMedicine #Bioinks #Innovation #Science